Go easy on me Greedy!  I just bought 500 shares of DNDN at $4.41 for this Seattle baby bio!

 

Dendreon Inc has recently submitted a biological license application (BLA) to the FDA for the the prostate cancer drug "Provenge".  Very interesting science.  They have priority review status!  This means the FDA should move on the clinical results for this drug by May/2007.

 

They diluted a few weeks ago and the stock dropped.  Based on where they are in the regulatory process and the PPS, I could not pass up the price for this drug at this late-stage development point.

 

This one is heavily talked about in "baby bio" circles.  It is more speculative than some other companies I have posted.  The FDA has not weighed in on this yet at all! Could easily get an approvable letter causing delays?   The company is rumored to be bought out heavily, but I doubt it until they get guidence from the FDA.  It is a big potential market though and I am there.

 

Check it out!

 

Kutz